講座編號：jz-yjsb-2021-y039
講座題目：Advanced in Vitro Test Systems in Respiratory Toxicology
主 講 人：張全順 研究員 美國體外科學研究院
講座時間：2021年10月13日（星期三）上午10:00
講座地點：阜成路校區教三樓334室
參加對象：化妝品專業的研究生、本科生和教師
主辦單位：化學與材料工程學院、研究生院
主講人簡介：
張全順，資深毒理學科學家，畢業于南京農業大學，現任美國體外科學研究所（Institute for In Vitro Sciences，IIVS）教育和外聯項目科學計劃主任。張全順博士曾在上海出入境檢驗檢疫局從事產品毒理學檢測及臨床安全評價工作，有十年的海關檢疫工作經驗，2000年在美國普洛威頓斯學院和塔夫茨大學從事產品安全檢測和臨床評價的研究工作，積累了豐富的化妝品產品研發，安全和功效評價經驗。目前他負責的化妝品體外安全功效評價教育和外聯項目主要在中國，巴西和俄羅斯進行。
主講內容：
The Family Smoking Prevention and Tobacco Control Act of 2009 facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. The 2007 report, “Toxicity Testing in the 21st Century – a Vision and a Strategy”, The National Academies Press, Washington D.C., describes a path forward for toxicology and envisions the use of more predictive human-relevant in vitro models for estimating human health risks. Aside from the ethical considerations and often poor predictive value of animal testing, the vast numbers of chemicals requiring evaluation will require a new strategy that many researchers believe depends upon the use of competent human-relevant, in vitro/ex vivo test systems applied in a pragmatic manner. Since 2013, the Institute for In Vitro Sciences, Inc. (IIVS) convened a series of workshop conferences: 1) Workshop on Inhalation Toxicity: Pathways to Better Methods (May 1-3, 2013); 2) Assessment of In Vitro COPD Models for Tobacco Regulatory Science (December 8-10, 2014); 3) Technical Workshop for Goblet Cell Hyperplasia, Mucus Production and Ciliary Beating Assays (June 16-18, 2015); and 4) In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products (April 4-6, 2016), to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP.
Collectively, In vitro models utilizing human-derived cell lines and primary cells provide endpoints that reflect cytotoxic, genotoxic, and other relevant adverse events following exposure to toxicants. More recently, the emergence of modern three-dimensional (3D) tissue culture systems of the respiratory tract provide toxicologists with test platforms that more accurately model the complex processes observed in native tissues that involve multiple cells types. Human donor-tissue derived spheroids/organoids, reconstructed human airways, and precision-cut lung slices provide conventional toxicity endpoints as well as more complex, relevant events that follow chemical exposure. The complement of multiple cell types, physiological structure, relevant toxicokinetics, and other properties of these models allow additional evaluations, including chronic-exposure related (e.g. inflammation), functional (e.g. ciliary beating assays), and other endpoints (e.g. Goblet cell hyperplasia) that can reflect more serious health complications that may lead to chronic obstructive pulmonary disease.
This presentation will provide an overview of in vitro/ex vivo pulmonary models and how they can be incorporated into a screening/testing strategy for chemicals/tobacco products that can include more complex human pulmonary adverse events that are evaluable in modern 3D systems.